Every batch of BPC-157 10mg is independently tested by a third-party analytical laboratory using HPLC for purity and mass spectrometry for identity confirmation
LC-MS combines liquid chromatography with mass spectrometry to separate, identify, and quantify molecular species by mass-to-charge ratio
SLU-PP-332 distribution The distribution pattern of SLU-PP-332 is characterized by: Rapid and extensive distribution to target tissues High volume of distribution, indicating good penetration into various body compartments Potential for crossing the blood-brain barrier, expanding its therapeutic potential These distribution characteristics may contribute to the versatility of SLU-PP-332 in treating various conditions
HGF targeting antibodies, including rilotumumab (AMG-102), ficlatuzumab, TAK-701, and YYB-101, bind to HGF and prevent c-Met attachment, leading to the induction of synergistic anti-tumor responses combined with other TKIs and EGFR inhibitors [162, 172, 178, 179]